Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
      Description

      The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

      Conditions
      Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or FusionAdvanced Solid Tumors With FGFR1 AmplicationAdvanced Solid Tumors With FGFR2 AmplicationAdvanced Solid Tumors With FGFR3 Mutation
      Talk to us
      RECRUITING
      Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
      Description

      BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.

      Conditions
      Non-small Cell Lung CancerNon-Small Cell Lung AdenocarcinomaNon-Small Cell Squamous Lung CancerHead and Neck Squamous Cell CarcinomaEsophageal CancerGastric CancerBreast CancerBladder CancerOvarian CancerEndometrial CancerLiposarcoma
      Talk to us
      TERMINATED
      A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
      Description

      The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGF), or platelet derived growth factor (PDGF) related genetic alterations.

      Conditions
      Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLCSmall Cell Lung CancerSCLCLung CancerAdvanced Lung CancerMetastatic Lung CancerStage IV Lung Cancer
      Talk to us